US › Healthcare

Traws Pharma Inc (TRAW)

US · Healthcare · Biotechnology

$0.55+17.32%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$57,000
Revenue YoY
0.0%
Net profit
$-7.1M
Profit YoY
-147.1%
EPS
$-0.52
EPS estimate
$-0.56
Net margin
-12,468.4%

EPS came in at -0.52 against a street estimate of -0.56 — a beat of 7.1%.

Key statistics

Market cap
$6.9M
Forward P/E
0.0
P/B
2.16
Book value
$-0.52
EPS (TTM)
$-1.87
52-week high
$3.27
52-week low
$0.43
50-day MA
$0.94
200-day MA
$1.67
Beta
1.51

Analyst view

Analysts rate Traws Pharma Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1.00.

Shareholding

Insiders
5.38%
Institutions
39.25%

Largest institutional holders

FundStake
Adage Capital Partners Gp LLC4.79%
Ikarian Capital, LLC4.45%
Orbimed Advisors, LLC3.98%
Squadron Capital Management LLC3.36%
Dauntless Investment Group, LLC2.74%
BOOTHBAY FUND MANAGEMENT, LLC1.28%
ADAR1 Capital Management LLC1.01%
Geode Capital Management, LLC0.51%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Traws Pharma Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.